Patrick R. O'neil Sells 1,207 Shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Stock

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Get Free Report) EVP Patrick R. O'neil sold 1,207 shares of the business's stock in a transaction that occurred on Thursday, February 20th. The shares were sold at an average price of $32.35, for a total value of $39,046.45. Following the completion of the sale, the executive vice president now owns 56,245 shares in the company, valued at $1,819,525.75. The trade was a 2.10 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link.

Ionis Pharmaceuticals Trading Up 0.0 %

IONS stock traded up $0.02 during trading on Thursday, hitting $31.78. 239,815 shares of the company traded hands, compared to its average volume of 1,644,963. The company has a 50-day moving average of $33.32 and a 200-day moving average of $37.98. The firm has a market capitalization of $5.05 billion, a PE ratio of -10.46 and a beta of 0.34. The company has a debt-to-equity ratio of 2.12, a quick ratio of 8.82 and a current ratio of 8.47. Ionis Pharmaceuticals, Inc. has a 1 year low of $30.23 and a 1 year high of $52.34.

Ionis Pharmaceuticals (NASDAQ:IONS - Get Free Report) last released its quarterly earnings results on Wednesday, February 19th. The company reported ($0.66) EPS for the quarter, beating analysts' consensus estimates of ($1.12) by $0.46. The business had revenue of $227.00 million during the quarter, compared to analyst estimates of $140.97 million. Ionis Pharmaceuticals had a negative return on equity of 100.05% and a negative net margin of 64.25%. Ionis Pharmaceuticals's quarterly revenue was down 30.2% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.12 EPS. Analysts predict that Ionis Pharmaceuticals, Inc. will post -3.5 earnings per share for the current fiscal year.

Remove Ads

Analyst Ratings Changes

Several research firms have weighed in on IONS. Citigroup lowered their price target on Ionis Pharmaceuticals from $67.00 to $64.00 and set a "buy" rating on the stock in a research report on Thursday, February 20th. Royal Bank of Canada reaffirmed an "outperform" rating and set a $70.00 price target on shares of Ionis Pharmaceuticals in a research report on Thursday, February 20th. Needham & Company LLC reaffirmed a "buy" rating and set a $60.00 price target on shares of Ionis Pharmaceuticals in a research report on Thursday, February 20th. Piper Sandler decreased their target price on Ionis Pharmaceuticals from $65.00 to $62.00 and set an "overweight" rating on the stock in a report on Thursday, November 14th. Finally, StockNews.com lowered Ionis Pharmaceuticals from a "hold" rating to a "sell" rating in a research note on Tuesday, November 12th. Two equities research analysts have rated the stock with a sell rating, five have assigned a hold rating, thirteen have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus target price of $60.00.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of IONS. Capital World Investors raised its position in Ionis Pharmaceuticals by 46.5% during the 4th quarter. Capital World Investors now owns 11,465,413 shares of the company's stock valued at $400,831,000 after purchasing an additional 3,637,041 shares during the last quarter. Norges Bank bought a new position in shares of Ionis Pharmaceuticals in the 4th quarter worth approximately $59,948,000. Vanguard Group Inc. increased its position in Ionis Pharmaceuticals by 9.4% during the 4th quarter. Vanguard Group Inc. now owns 16,472,539 shares of the company's stock valued at $575,880,000 after buying an additional 1,416,781 shares in the last quarter. Vestal Point Capital LP purchased a new position in shares of Ionis Pharmaceuticals in the 4th quarter worth $20,801,000. Finally, Orbimed Advisors LLC lifted its position in Ionis Pharmaceuticals by 21.2% during the fourth quarter. Orbimed Advisors LLC now owns 2,817,347 shares of the company's stock valued at $98,494,000 after purchasing an additional 492,900 shares in the last quarter. Institutional investors own 93.86% of the company's stock.

Ionis Pharmaceuticals Company Profile

Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy.